Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia
- 284 Downloads
Adamantinoma of long bones (ALB) and osteofibrous dysplasia (OFD) are rare osteolytic bone tumours that principally arise in the tibia. Both ALB and OFD contain epithelial and stromal elements, as well as areas of fibro-osseous proliferation. We assessed expression of podoplanin, a glycoprotein found in osteocytes, in OFD and ALB as well as in fibrous dysplasia and metastatic cancer. Forty-two cases of ALB and OFD, 20 cases of fibrous dysplasia and 20 cases of metastatic carcinoma to bone were stained by immunohistochemistry for expression of podoplanin, epithelial (cytokeratin, epithelial membrane antigen) and vascular (CD34, LYVE-1) markers. Podoplanin was expressed in epithelial cells and tumour glands in ALB as well as in scattered intertrabecular stromal cells in both ALB and OFD. Podoplanin was not expressed by intertrabecular stromal cells in fibrous dysplasia or in metastatic adenocarcinoma. Podoplanin was expressed by osteocytes but not osteoblasts of woven and lamellar bone trabeculae in ALB, OFD, fibrous dysplasia and skeletal metastases. The finding of a common osteocyte marker in OFD/ALB stromal cells is in keeping with a close histogenetic relationship between OFD and ALB; this may reflect the prominence of fibro-osseous proliferation in these tumours. The expression of podoplanin in an osteolytic tumour of the tibia may be useful as a diagnostic discriminant in distinguishing OFD from fibrous dysplasia and ALB from metastatic adenocarcinoma.
KeywordsPodoplanin Osteofibrous dysplasia Adamantinoma of long bone Fibrous dysplasia Bone tumour Metastasis
The authors would like to thank Chris Lowe for typing the manuscript. This study was carried out by the EuroBoNet consortium, a Network of Excellence funded by the European Union.
Conflicts of interest
We declare that we have no conflicts of interest.
- 1.Hogendoorn PCW, Hashimoto H (2002) Adamantinoma. In: Fletcher C, Unni K, Mertens F (eds) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 332–334Google Scholar
- 2.Unni KK, Inwards YI, Bridge AN, Kindblom LG, Wold EW (2005) Tumors of the bones and joints AFIP atlas of tumor pathology. AFIP, pp. 281–298Google Scholar
- 3.Vigorita VJ, Whelman B, Hogendoorn PCW (2002) Osteofibrous dysplasia. In: Fletcher C, Unni K, Mertens F (eds) Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 332–334Google Scholar
- 4.Benassi MS, Campanacci L, Gamberi G, Ferrari C, Picci P, Sangiorgi L, Campanacci M (1994) Cytokeratin expression and distribution in adamantinoma of the long bones and osteofibrous dysplasia of tibia and fibula. An immunohistochemical study correlated to histogenesis. Histopathology 25:71–76PubMedCrossRefGoogle Scholar
- 9.Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMedCrossRefGoogle Scholar
- 27.Lichtenstein L (1997) Dermal inclusion tumours in bone (so-called adamantinoma of limb bones). In: Lichtenstein L (ed) Bone Tumours. C.V. Mosby Co., St. Louis, pp 355–362Google Scholar
- 33.Maki M, Saitoh K, Kaneko Y, Fukayama M, Morohoshi T (2000) Expression of cytokeratin 1, 5, 14, 19 and transforming growth factors-beta1, beta2, beta3 in osteofibrous dysplasia and adamantinoma: a possible association of transforming growth factor-beta with basal cell phenotype promotion. Pathol Int 50:801–807PubMedCrossRefGoogle Scholar